Neuvax finally completed a phase III trial, which evaluated the vaccine in combination with GM-CSF vs. placebo plus GM-CSF to prevent recurrence in BC patients with node positive, HER2 low expression, and HLA-A2+/A3+ (NTC01479244). The gene discussed is CSF2; the disease is breast cancer.